Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
100 results
  • Leukemia

23-031          Phase I

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

  • Lung Cancer

23-075          Phase I

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

  • Lung Cancer

23-568          Phase I

A phase 1 study evaluating the safety, tolerability, and efficacy of bl-b01d1 in subjects with metastatic or unresectable non-small cell lung cancer and other solid tumors

  • Breast Cancer, Cervical Cancer, Esophageal Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer

22-281          Phase I

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors

  • Multiple Myeloma

22-644          Phase I

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma

  • Leukemia

20-191          Phase I

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

  • Pancreatic Cancer, Gastric (Stomach) Cancer, Esophageal Cancer

21-385          Phase I

A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

  • Lymphoma

23-330          Phase I

A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)

  • Cellular Therapy

2024P001014          Phase I

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis

  • Head and Neck Cancer, Esophageal Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

Showing 21 - 30 of 100 results